Find Lumacaftor manufacturers, exporters & distributors on PharmaCompass

Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

Virtual Booth

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

8 API Suppliers, 1 USDMF, 1 EU WC, 2 NDC API, 8 Listed Suppliers, $ API Reference Price

8 API Suppliers
1 USDMF
1 EU WC
2 NDC API
8 Listed Suppliers
$ API Reference Price

DEVELOPMENTS

4 Drugs in Development

4 Drugs in Development

INTERMEDIATES

3 Intermediates Suppliers

3 Intermediates Suppliers

FINISHED DOSAGE FORMULATIONS

15 FDF Dossiers, 5 FDA Orange Book, 5 Europe, 5 Canada

15 FDF Dossiers
5 FDA Orange Book
5 Europe
5 Canada

RELATED EXCIPIENT COMPANIES

1 SPI Pharma, 3 DKSH, 4 Faran Shimi Pharmaceutical, 1 Boai NKY Pharmaceuticals Ltd, 8 Gangwal Healthcare, 2 Nanjing Well Pharmaceutical, 1 Aeon Procare, 4 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 16 BASF, 5 Corel Pharma Chem, 3 DFE Pharma, 1 Finar, 7 Gangwal Chemicals, 3 Ideal Cures Pvt Ltd, 1 Ingredion Pharma Solutions, 6 Kerry, 1 Lonza Capsugel, 8 Microlex e.U, 2 Novo Excipients, 2 Pharmatrans-Sanaq, 4 Pluviaendo, 3 Prachin Chemical, 10 Roquette, 1 Seppic, 3 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 10 Sigachi Industries, 2 The Dow Chemical Company, 1 Valens Pharmachem, 3 Vasa Pharmachem

EXCIPIENTS BY APPLICATIONS

29 Fillers, Diluents & Binders, 25 Coating Systems & Additives, 19 Direct Compression, 16 Disintegrants & Superdisintegrants, 15 Lubricants & Glidants, 15 Granulation, 14 Controlled & Modified Release, 12 Thickeners and Stabilizers, 9 Co-Processed Excipients, 9 Solubilizers, 8 Film Formers & Plasticizers, 6 Topical, 5 Parenteral, 5 Taste Masking, 3 Coloring Agents, 2 Emulsifying Agents, 2 Rheology Modifiers, 2 Chewable & Orodispersible Aids, 1 Vegetarian Capsules, 1 Surfactant & Foaming Agents, 1 API Stability Enhancers

DIGITAL CONTENT

2 DATA COMPILATION #PharmaFlow, 63 NEWS #PharmaBuzz

media
2 DATA COMPILATION #PharmaFlow
63 NEWS #PharmaBuzz

GLOBAL SALES INFORMATION

5 Finished Drug Prices, 8 Annual Reports

globalSalesInformation
5 Finished Drug Prices
8 Annual Reports

MARKET PLACE

3 APIs, 1 FDF Dossiers

marketPlace
3 APIs
1 FDF Dossiers

PATENTS & EXCLUSIVITIES

107 US Patents, 8 US Exclusivities

patents
107 US Patents
8 US Exclusivities

Synopsis

ACTIVE PHARMA INGREDIENTS

API Suppliers

USDMF

CEP/COS

JDMF

EU WC

KDMF

NDC API

VMF

Listed Suppliers

API REF. PRICE (USD/KG)

$ 24,833

MARKET PLACE

API

FDF

3INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

FDF Dossiers

FDA Orange Book

Europe

Canada

Australia

South Africa

Listed Dossiers

4DRUGS IN DEVELOPMENT

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

EDQM

USP

Others

PATENTS & EXCLUSIVITIES

107

US Patents

US Exclusivities

Health Canada Patents

DIGITAL CONTENT

Data Compilation #PharmaFlow

Stock Recap #PipelineProspector

Weekly News Recap #Phispers

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid (USD)

Annual Reports (USD Million)

7,256

Finished Drug Prices

116 RELATED EXCIPIENT COMPANIES

199EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

Also known as: 936727-05-8, Vx-809, Vx 809, Vx809, Vrt-826809, 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid

Molecular Formula

C₂₄H₁₈F₂N₂O₅

Molecular Weight

452.4 g/mol

InChI Key

UFSKUSARDNFIRC-UHFFFAOYSA-N

FDA UNII

EGP8L81APK

Lumacaftor is a drug used in combination with [DB08820] as the fixed dose combination product Orkambi for the management of Cystic Fibrosis (CF) in patients aged 6 years and older. Cystic Fibrosis is an autosomal recessive disorder caused by one of several different mutations in the gene for the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) protein, a transmembrane ion channel involved in the transport of chloride and sodium ions across cell membranes of the lungs, pancreas, and other organs. Mutations in the CFTR gene result in altered production, misfolding, or function of the CFTR protein and consequently abnormal fluid and ion transport across cell membranes. As a result, CF patients produce thick, sticky mucus that clogs the ducts of organs where it is produced making patients more susceptible to infections, lung damage, pancreatic insufficiency, and malnutrition. Lumacaftor improves CF symptoms and underlying disease pathology by aiding the conformational stability of F508del-mutated CFTR proteins, preventing misfolding and resulting in increased processing and trafficking of mature protein to the cell surface. Results from clinical trials indicated that treatment with Orkambi (lumacaftor/ivacaftor) results in improved lung function, reduced chance of experiencing a pulmonary exacerbation, increased weight gain, and improvements in CF symptoms. This data has been heavily scrutinized, however, with clinical trials showing only modest improvements despite a hefty yearly cost of $259,000 for Orkambi. Improvements in lung function (ppFEV1) were found to be statistically significant, but minimal, with only a 2.6-3.0% change from baseline with more than 70% of patients failing to achieve an absolute improvement of at least 5%. A wide variety of CFTR mutations correlate to the Cystic Fibrosis phenotype and are associated with differing levels of disease severity. The most common mutation, affecting approximately 70% of patients with CF worldwide, is known as F508del-CFTR, or delta-F508 (F508), in which a deletion in the amino acid phenylalanine at position 508 results in impaired production of the CFTR protein, thereby causing a significant reduction in the amount of ion transporter present on cell membranes. When used in combination with [DB08820] as the fixed dose combination product Orkambi, lumacaftor is specific for the management of CF in patients with delta-F508 mutations as it acts as a protein-folding chaperone, aiding the conformational stability of the mutated CFTR protein. Consequently, lumacaftor increases successful production of CFTR ion channels and the total number of receptors available for use at the cell membrane for fluid and ion transport. The next most common mutation, G551D, affecting 4-5% of CF patients worldwide, is characterized as a missense mutation, whereby there is sufficient amount of protein at the cell surface, but opening and closing mechanisms of the channel are altered. Treatment of patients with G551D and other rarer missense mutations is usually managed with [DB08820] (Kalydeco), as it aids with altered gating mechanisms by potentiating channel opening probability of CFTR protein. Prior to the development of lumacaftor and [DB08820] (Kalydeco), management of CF primarily involved therapies for the control of infections, nutritional support, clearance of mucus, and management of symptoms rather than improvements in the underlying disease process. Approved for use by the Food and Drug Administration in July 2015 and by Health Canada in January 2016, Orkambi was the first combination product approved for the management of Cystic Fibrosis with delta-F508 mutations. Ivacaftor is manufactured and distributed by Vertex Pharmaceuticals.

The mechanism of action of lumacaftor is as a Cytochrome P450 3A Inducer, and Cytochrome P450 2B6 Inducer, and Cytochrome P450 2C8 Inducer, and Cytochrome P450 2C9 Inducer, and Cytochrome P450 2C19 Inducer, and Cytochrome P450 2C8 Inhibitor, and Cytochrome P450 2C9 Inhibitor, and P-Glycoprotein Inducer, and P-Glycoprotein Inhibitor.

1 2D Structure

Lumacaftor

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

3-[6-[[1-(2,2-difluoro-1,3-benzodioxol-5-yl)cyclopropanecarbonyl]amino]-3-methylpyridin-2-yl]benzoic acid

2.1.2 InChI

InChI=1S/C24H18F2N2O5/c1-13-5-8-19(27-20(13)14-3-2-4-15(11-14)21(29)30)28-22(31)23(9-10-23)16-6-7-17-18(12-16)33-24(25,26)32-17/h2-8,11-12H,9-10H2,1H3,(H,29,30)(H,27,28,31)

2.1.3 InChI Key

UFSKUSARDNFIRC-UHFFFAOYSA-N

2.1.4 Canonical SMILES

CC1=C(N=C(C=C1)NC(=O)C2(CC2)C3=CC4=C(C=C3)OC(O4)(F)F)C5=CC(=CC=C5)C(=O)O

2.2 Other Identifiers

2.2.1 UNII

EGP8L81APK

2.3 Synonyms

2.3.1 MeSH Synonyms

1. Vx 809

2. Vx-809

3. Vx809

2.3.2 Depositor-Supplied Synonyms

1. 936727-05-8

2. Vx-809

3. Vx 809

4. Vx809

5. Vrt-826809

6. 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic Acid

7. Vrt 826809

8. Vx-809 (lumacaftor)

9. Egp8l81apk

10. 3-(6-{[1-(2,2-difluoro-benzo[1,3]dioxol-5-yl)-cyclopropanecarbonyl]-amino}-3-methyl-pyridin-2-yl)-benzoicacid

11. 3-(6-{[1-(2,2-difluoro-benzo[1,3]dioxol-5-yl)-cyclopropanecarbonyl]-amino}-3-methyl-pyridin-2-yl)-benzoic Acid

12. 3-[6-[[1-(2,2-difluoro-1,3-benzodioxol-5-yl)cyclopropanecarbonyl]amino]-3-methylpyridin-2-yl]benzoic Acid

13. Lumacaftor (usan)

14. 3-(6-{[1-(2,2-difluoro-2h-1,3-benzodioxol-5-yl)cyclopropane-1-carbonyl]amino}-3-methylpyridin-2-yl)benzoic Acid

15. Lumacaftor [usan]

16. 3-(6-(1-(2,2-difluoro-1,3-benzodioxol-5-yl)cyclopropane-1-carboxamido)-3-methylpyridin-2-yl)benzoic Acid

17. 3-(6-[[1-(2,2-difluoro-benzo[1,3]dioxol-5-yl)-cyclopropanecarbonyl]-amino]-3-methyl-pyridin-2-yl)-benzoic Acid

18. 3-(6-{[1-(2,2-difluoro-benzo[1,3]dioxol-5-yl)-cyclopropanecarbonyl]-amino}-3-methyl-pyridin-2-yl)-be

19. 3-(6-{[1-(2,2-difluorobenzo[1,3]dioxol-5-yl)cyclopropanecarbonyl]-amino}-3-methyl-pyridin-2-yl)benzoic Acid

20. Benzoic Acid, 3-(6-(((1-(2,2-difluoro-1,3-benzodioxol-5-yl)cyclopropyl)carbonyl)amino)-3-methyl-2-pyridinyl)-

21. Lumacaftor [inn]

22. Lumacaftor [usan:inn]

23. Unii-egp8l81apk

24. Vx8

25. Lumacaftor [mi]

26. Lumacaftor (vx-809)

27. Lumacaftor [who-dd]

28. Lumacaftor(vx-809vx809)

29. Mls006011120

30. Schembl377028

31. Gtpl7481

32. Chembl2103870

33. Lumacaftor [orange Book]

34. Chebi:90951

35. Dtxsid30239523

36. Ex-a178

37. Hms3655e05

38. Orkambi Component Lumacaftor

39. Amy14931

40. Bcp02305

41. Bdbm50289703

42. Mfcd16659051

43. S1565

44. Zinc64033452

45. Akos015920205

46. Lumacaftor Component Of Orkambi

47. Ccg-269253

48. Cs-0479

49. Db09280

50. Pb19466

51. Ncgc00346550-01

52. Ncgc00346550-02

53. Ncgc00346550-05

54. Ac-23172

55. As-31756

56. Hy-13262

57. Smr004702901

58. Ft-0757817

59. Sw219911-1

60. A25628

61. D10134

62. J-690399

63. Q6703005

64. 3-(6-(1-(2,2-difluorobenzo(d) (1,3)dioxyl-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic Acid

65. 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) Cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic Acid

66. 3-(6-{[1-(2,2-difluoro-2h-1,3-benzodioxol-5-yl)cyclopropane-1-carbonyl]amino}-3-methylpyridin-2-yl)benzoic Acid; Vx-809

67. 3-(6-{[1-(2,2-difluorobenzo[1,3]dioxol-5-yl)cyclopropanecarbonyl]amino}-3-methyl-pyridin-2-yl)benzoic Acid

2.4 Create Date

2007-08-20

3 Chemical and Physical Properties

Molecular Formula	C₂₄H₁₈F₂N₂O₅
Molecular Weight	452.4 g/mol
XLogP3	4.4
Hydrogen Bond Donor Count	2
Hydrogen Bond Acceptor Count	8
Rotatable Bond Count	5
Exact Mass	452.11837800 g/mol
Monoisotopic Mass	452.11837800 g/mol
Topological Polar Surface Area	97.8 Å²
Heavy Atom Count	33
Formal Charge	0
Complexity	776
Isotope Atom Count	0
Defined Atom Stereocenter Count	0
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1

4 Drug and Medication Information

4.1 Drug Indication

When given in combination with [DB08820] as the fixed dose combination product Orkambi, lumacaftor is indicated for the treatment of cystic fibrosis (CF) in patients age 6 years and older who are homozygous for the F508del mutation in the CFTR gene.

FDA Label

Treatment of cystic fibrosis

5 Pharmacology and Biochemistry

5.1 Pharmacology

Results from clinical trials indicated that treatment with Orkambi (lumacaftor/ [DB08820]) results in improved lung function, reduced chance of experiencing a pulmonary exacerbation, reduced sweat chloride, increased weight gain, and improvements in CF symptoms and quality of life. Orkambi was not found to increase the QTc interval to any clinically relevant extent.

5.2 FDA Pharmacological Classification

5.2.1 Active Moiety

LUMACAFTOR

5.2.2 FDA UNII

EGP8L81APK

5.2.3 Pharmacological Classes

Mechanisms of Action [MoA] - P-Glycoprotein Inhibitors

5.3 ATC Code

R07AX30

S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (in prep.). List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355

5.4 Absorption, Distribution and Excretion

Absorption

Following administration of Orkambi (lumacaftor/[DB08820]) with fat containing foods, peak plasma concentrations were reached at 4 hours (Tmax). It's recommended that Orkambi should be taken with fat-containing foods as they increase absorption of lumacaftor by approximately 2-fold, and[DB08820 by 3-fold.

Route of Elimination

Lumacaftor is primarily excreted unchanged in the feces (51%). A minimal amount of the parent compound and its metabolites are excreted in the urine.

Volume of Distribution

Following oral administration of 200 mg of lumacaftor every 24 hours to cystic fibrosis patients in a fed state for 28 days, the mean (+/-SD) for apparent volumes of distribution was 86.0 (69.8) L.

Clearance

The typical apparent clearance, CL/F (CV), of lumacaftor was estimated to be 2.38 L/hr.

5.5 Metabolism/Metabolites

Lumacaftor is mostly excreted unchanged in the feces and is not extensively metabolized. When metabolism does occur, oxidation and glucuronidation are the main processes involved.

5.6 Biological Half-Life

The half-life of lumacaftor is approximately 26 hours.

5.7 Mechanism of Action

Lumacaftor improves CF symptoms and underlying disease pathology by aiding the conformational stability of F508del-mutated CFTR, resulting in increased processing and trafficking of mature protein to the cell surface. More specifically, lumacaftor acts as a protein-folding chaperone, preventing misfolding of CFTR ion channels and consequent destruction during processing in the endoplasmic reticulum.

API SUPPLIERS

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

USDMF

01

Maithri Drugs Private Ltd

India

Pharma, Lab & Chemical Expo

Not Confirmed

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Listed Suppliers

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

API Reference Price

Number of Transactions

Total Quantity (KGS)

Total Value (USD)

Quantity (KGS) & Unit rate (USD/KGS) over time

API Imports and Exports

Importing Country	Total Quantity (KGS)	Average Price (USD/KGS)	Number of Transactions

Upgrade, download data, analyse, strategize, subscribe with us contact

Drugs in Development

01 Vertex Pharmaceuticals

U.S.A

Pharma, Lab & Chemical Expo

Not Confirmed

02 Vertex Pharmaceuticals

U.S.A

Pharma, Lab & Chemical Expo

Not Confirmed

03 Vertex Pharmaceuticals

U.S.A

Pharma, Lab & Chemical Expo

Not Confirmed

04 Vertex Pharmaceuticals

U.S.A

Pharma, Lab & Chemical Expo

Not Confirmed

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

INTERMEDIATES SUPPLIERS

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

FDF Dossiers

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

FDA Orange Book

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Europe

01

Vertex Solvay (U.K.) Limited - Rickmansw...

U.S.A

U.S.A

Pharma, Lab & Chemical Expo

U.S.A

Pharma, Lab & Chemical Expo

Not Confirmed

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Related Excipient Companies

Upload your portfolio for free, ask us

Excipients by Applications

Click here to find the perfect excipient manufacturers by their capabilities

Fillers, Diluents & Binders

Coating Systems & Additives

Direct Compression

Disintegrants & Superdisintegrants

Lubricants & Glidants

Granulation

Controlled & Modified Release

Thickeners and Stabilizers

Co-Processed Excipients

Solubilizers

Film Formers & Plasticizers

Topical

Parenteral

Taste Masking

Coloring Agents

Emulsifying Agents

Rheology Modifiers

Chewable & Orodispersible Aids

Vegetarian Capsules

Surfactant & Foaming Agents

API Stability Enhancers

Digital Content

Create Content with PharmaCompass, ask us

DATA COMPILATION #PharmaFlow

NEWS #PharmaBuzz

Global Sales Information

Do you need Business Intel? Ask us

Finished Drug Prices

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Annual Reports

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Market Place

Do you need sourcing support? Ask us

APIs

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

FDF DOSSIERS

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

US Patents

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

US Exclusivities

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

ABOUT THIS PAGE

Lumacaftor Manufacturers

A Lumacaftor manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Lumacaftor, including repackagers and relabelers. The FDA regulates Lumacaftor manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Lumacaftor API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

click here to find a list of Lumacaftor manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.

Lumacaftor Suppliers

A Lumacaftor supplier is an individual or a company that provides Lumacaftor active pharmaceutical ingredient (API) or Lumacaftor finished formulations upon request. The Lumacaftor suppliers may include Lumacaftor API manufacturers, exporters, distributors and traders.

click here to find a list of Lumacaftor suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.

Lumacaftor USDMF

A Lumacaftor DMF (Drug Master File) is a document detailing the whole manufacturing process of Lumacaftor active pharmaceutical ingredient (API) in detail. Different forms of Lumacaftor DMFs exist exist since differing nations have different regulations, such as Lumacaftor USDMF, ASMF (EDMF), JDMF, CDMF, etc.

A Lumacaftor DMF submitted to regulatory agencies in the US is known as a USDMF. Lumacaftor USDMF includes data on Lumacaftor's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Lumacaftor USDMF is kept confidential to protect the manufacturer’s intellectual property.

click here to find a list of Lumacaftor suppliers with USDMF on PharmaCompass.

Lumacaftor WC

A Lumacaftor written confirmation (Lumacaftor WC) is an official document issued by a regulatory agency to a Lumacaftor manufacturer, verifying that the manufacturing facility of a Lumacaftor active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Lumacaftor APIs or Lumacaftor finished pharmaceutical products to another nation, regulatory agencies frequently require a Lumacaftor WC (written confirmation) as part of the regulatory process.

click here to find a list of Lumacaftor suppliers with Written Confirmation (WC) on PharmaCompass.

Lumacaftor NDC

National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Lumacaftor as an active pharmaceutical ingredient (API).

Finished drug products

The FDA updates the NDC directory daily. The NDC numbers for Lumacaftor API and other APIs are published in this directory by the FDA.

Unfinished drugs

The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

Pharmaceutical companies that manufacture Lumacaftor as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

Compounded drug products

The NDC directory also contains data on finished compounded human drug products that contain Lumacaftor and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Lumacaftor NDC to their finished compounded human drug products, they may choose to do so.

click here to find a list of Lumacaftor suppliers with NDC on PharmaCompass.

Lumacaftor GMP

Lumacaftor Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Lumacaftor GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Lumacaftor GMP manufacturer or Lumacaftor GMP API supplier for your needs.

Lumacaftor CoA

A Lumacaftor CoA (Certificate of Analysis) is a formal document that attests to Lumacaftor's compliance with Lumacaftor specifications and serves as a tool for batch-level quality control.

Lumacaftor CoA mostly includes findings from lab analyses of a specific batch. For each Lumacaftor CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Lumacaftor may be tested according to a variety of international standards, such as European Pharmacopoeia (Lumacaftor EP), Lumacaftor JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Lumacaftor USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.

Market Place

Home

Post Enquiry

Market Place

Find Lumacaftor manufacturers, exporters & distributors on PharmaCompass

ACCESS ALL DATA

Browse all information

CHEMISTRY

Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

8 API Suppliers

1 USDMF

1 EU WC

2 NDC API

8 Listed Suppliers

$ API Reference Price

DEVELOPMENTS

4 Drugs in Development

INTERMEDIATES

3 Intermediates Suppliers

FINISHED DOSAGE FORMULATIONS

15 FDF Dossiers

5 FDA Orange Book

5 Europe

5 Canada

RELATED EXCIPIENT COMPANIES

1 SPI Pharma

3 DKSH

4 Faran Shimi Pharmaceutical

1 Boai NKY Pharmaceuticals Ltd

8 Gangwal Healthcare

2 Nanjing Well Pharmaceutical

1 Aeon Procare

4 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd

16 BASF

5 Corel Pharma Chem

3 DFE Pharma

1 Finar

7 Gangwal Chemicals

3 Ideal Cures Pvt Ltd

1 Ingredion Pharma Solutions

6 Kerry

1 Lonza Capsugel

8 Microlex e.U

2 Novo Excipients

2 Pharmatrans-Sanaq

4 Pluviaendo

3 Prachin Chemical

10 Roquette

1 Seppic

3 Shanghai Shenmei Pharmaceutical Technology Co., Ltd

10 Sigachi Industries

2 The Dow Chemical Company

1 Valens Pharmachem

3 Vasa Pharmachem

EXCIPIENTS BY APPLICATIONS

29 Fillers, Diluents & Binders

25 Coating Systems & Additives

19 Direct Compression

16 Disintegrants & Superdisintegrants

15 Lubricants & Glidants

15 Granulation

14 Controlled & Modified Release

12 Thickeners and Stabilizers

9 Co-Processed Excipients

9 Solubilizers

8 Film Formers & Plasticizers

6 Topical

5 Parenteral

5 Taste Masking

3 Coloring Agents

2 Emulsifying Agents

2 Rheology Modifiers

2 Chewable & Orodispersible Aids

1 Vegetarian Capsules

1 Surfactant & Foaming Agents

1 API Stability Enhancers

DIGITAL CONTENT

2 DATA COMPILATION #PharmaFlow

63 NEWS #PharmaBuzz

GLOBAL SALES INFORMATION

5 Finished Drug Prices

8 Annual Reports

MARKET PLACE